Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a solution for injection for subcutaneous use. It prevents clot formation in patients at risk of deep vein thrombosis, pulmonary embolism, and during hemodialysis procedures.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Innohep, a low molecular weight heparin, is used in several clinical situations to prevent or treat thromboembolic disorders.

- Prevention of deep vein thrombosis in surgical patients: reduces the incidence of postoperative clot formation. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension. - Prevention of pulmonary embolism: lowers the risk of embolic events in at‑risk individuals. - Prevention of clot formation in hemodialysis: maintains circuit patency during dialysis sessions.

Tinzaparin sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site erythema: redness at the subcutaneous injection site. - Pain or bruising: mild discomfort or discoloration around the injection area. - Minor bleeding: nosebleeds, gum bleeding, or easy bruising. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Major bleeding: life‑threatening hemorrhage such as gastrointestinal or intracranial bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clotting. - Spinal or epidural hematoma: bleeding in the spinal canal following neuraxial procedures. - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Skin necrosis: localized tissue death at injection sites.

When using Innohep, several precautionary measures should be observed to minimize risk.

- Renal impairment: adjust dosing and monitor anti‑Xa activity. - History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence. - Concurrent anticoagulants or antiplatelet agents: assess cumulative bleeding risk. - Recent surgery or trauma: evaluate for potential bleeding complications. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with other medicines, altering bleeding risk or anticoagulant effect.

Major Interactions (Avoid): - Concomitant use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increases risk of severe bleeding. - Antiplatelet agents (e.g., aspirin, clopidogrel): additive effect on bleeding. - Thrombolytic therapy (e.g., alteplase): synergistic hemorrhagic potential.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs): can increase bleeding tendency. - Systemic corticosteroids: may exacerbate bleeding risk.